NCT06847399 - Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

September 17, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2027

Conditions

Obesity and OverweightBinge Eating Disorder

Interventions

DRUG

Tirzepatide

DRUG

Lisdexamfetamine Dimesylate

Lisdexamfetamine dimesylate

BEHAVIORAL

Guided self-help cognitive behavioral therapy

DRUG

Placebo (oral)

DRUG

Placebo (injection)

Trial Locations (1)

RECRUITING

Johns Hopkins University, Baltimore

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

Johns Hopkins University

OTHER